00:17 , May 18, 2019 |  BioCentury  |  Politics, Policy & Law

Cutting through the noise: the handful of pricing proposals the Trump administration or Congress may enact

Scores of proposals for reducing the cost of drugs are swirling around Congress, the White House and the U.S. Department of Health and Human Services, but only a few merit attention outside the beltway. Eliminating...
23:07 , May 16, 2019 |  BC Extra  |  Politics & Policy

CMS drops Trump administration proposal to negotiate protected class coverage

CMS will not implement a proposed change to Medicare Part D that would have allowed plans to exclude some drugs in six protected therapeutic classes from their formularies, but will allow for broader use of...
21:07 , May 8, 2019 |  BC Extra  |  Politics & Policy

Azar backs drug importation as he unveils final TV ad rule

In a press briefing announcing a final rule on disclosure of drug prices in television advertisements, HHS Secretary Alex Azar Wednesday expressed his and President Donald Trump’s support for drug importation. “The president and I...
14:31 , Apr 26, 2019 |  BC Extra  |  Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans...
22:17 , Apr 22, 2019 |  BC Extra  |  Politics & Policy

Medicare predicts smaller increases in annual Part D drug spending

While the Medicare Board of Trustees reported that Part D drug spending in 2018 came in slightly higher than predicted, it lowered its projected growth rates for the next five years due to slower price...
23:16 , Apr 16, 2019 |  BC Extra  |  Company News

Management tracks: Ginkgo Bioworks, KSQ, Milestone, Cerebral

Genetic engineering company Ginkgo Bioworks Inc. (Boston, Mass.) appointed Marijn Dekkers as chairman and strategic adviser. He was CEO of Bayer AG (Xetra:BAYN) and is currently chairman of Unilever plc (LSE:ULVR), Unilever N.V. (NYSE:UL) and...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
21:46 , Mar 29, 2019 |  BC Extra  |  Financial News

Blueprint raises $300M in follow-on, speeds regulatory timelines

Days after revealing new timelines for its lead program, Blueprint raised $300 million in a follow-on priced late Thursday. Blueprint Medicines Corp. (NASDAQ:BPMC) sold 4.1 million shares at $74, a 7% discount to the company's...
15:20 , Mar 26, 2019 |  BC Extra  |  Politics & Policy

DOJ supports ruling to strike down ACA, including biosimilars provisions

The FDA's biosimilar pathway would be swept away if the Trump administration's decision to back a court ruling results in striking down the entirety of the Affordable Care Act. In a letter to the U.S....
14:30 , Mar 19, 2019 |  BC Innovations  |  Distillery Therapeutics

ALK2 inhibition for diffuse intrinsic pontine glioma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Cell culture and mouse studies suggest inhibiting ALK2 could help treat diffuse intrinsic pontine glioma (DIPG) in patients harboring activating ALK2 mutations. In tumorspheres derived from an ALK2-mutant mouse...